| Ticker: | ALLO |
| Current Price: | $0.84 |
| % Daily Change: | 1.41% |
| Volume (1,000s): | 11,543.60 |
| Average Volume (1,000s): | 8,034.01 |
| Market Cap (M): | $290.58 |
| 1/2/2024 Price: | $2.24 |
| Change Since Inception: | -62.50% |
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, CA 94080
United States
Allogene Therapeutics is a clinical-stage biotechnology company with a single-minded focus on pioneering the development of investigational allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by world-class management with significant experience in cell therapy, our fully integrated, in-house team of researchers is dedicated to discovery and translational research, development, and cell manufacturing.
At Allogene, we are developing a pipeline of “off-the-shelf” CAR T cell candidates, with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.